Lamin A/C Cardiomyopathy: Implications for Treatment.
Suet Nee Chen1, Orfeo Sbaizero1,2, Matthew R G Taylor1
1Molecular Genetics, Cardiovascular Institute, University of Colorado Denver Anschutz Medical Campus, 12700 E 19th Ave #F442, Aurora, CO, 80045-2507, USA.
Current Cardiology Reports
|November 28, 2019
Summary
Lamin A/C (LMNA)-related cardiomyopathy, a common inherited heart condition, progresses to heart failure and sudden death. Research is exploring new molecular targets and therapies like gene silencing and editing for improved patient outcomes.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Lamin A/C (LMNA)-related cardiomyopathy is an inherited autosomal dominant disorder.
- It is a leading cause of dilated cardiomyopathy, marked by progressive heart failure.
- Patients face significant risks of arrhythmias and sudden cardiac death.
Purpose of the Study:
- To review current management strategies for LMNA-related cardiomyopathy.
- To update on recent advancements in understanding the disease's molecular mechanisms.
- To highlight emerging therapeutic targets and future treatment approaches.
Main Methods:
- Review of current literature on LMNA-related cardiomyopathy.
- Analysis of recent findings in molecular mechanisms and cell biomechanics.
- Discussion of ongoing and future clinical trials and therapeutic strategies.
Main Results:
- Altered cell biomechanics identified as a potential therapeutic target.
- Novel therapeutic approaches include repurposed drugs, siRNA gene silencing, and genome editing.
- Active research is generating new biomarkers and potential treatments for LMNA-related cardiomyopathy.
Conclusions:
- LMNA-related cardiomyopathy requires updated management beyond standard heart failure recommendations.
- Emerging molecularly targeted therapies hold promise for treating this condition.
- Ongoing research and clinical trials are crucial for advancing patient care.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
282
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
282
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
325
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
325
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
402
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
402
01:30Cardiomyopathy II: Dilated Cardiomyopathy
405
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
405
01:25Cardiomyopathy I: Introduction and Classification
442
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
442
01:29Cardiomyopathy VI: Nursing Management
261
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
261